Switching REMS Vendors: AAM Calls For FDA Guidance On Performance Standards

The trade association says it is impractical for a sponsor or REMS administrator to conduct a ‘failure modes and effects analysis’ to plan for system failures while United BioSource and the National Council for Prescription Drug Programs supports the testing.

Risk mitigation
The FDA gets advice on dealing with changes in vendors administering Risk Evaluation and Mitigation Strategies • Source: Shutterstock

The Association for Accessible Medicines recommends that the US Food and Drug Administration provide guidance on operational performance standards for Risk Evaluation and Mitigation Strategies (REMS) administration and hold a public meeting on obtaining stakeholder input and testing new REMS components.

AAM, a generic industry trade association, submitted comments to the agency on factors that should be considered when reviewing requests from sponsors to change third-party REMS vendors. The FDA was required to open a public docket and seek comments under a provision in the 2022 Food and Drug Omnibus Reform Act (FDORA)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By 

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

US FDA Expands Surprise Foreign Inspections

 
• By 

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By 

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.